29. Toxicology Emergencies

Published on 14/03/2015 by admin

Filed under Emergency Medicine

Last modified 14/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2205 times

Toxicology Emergencies

Edited by Mark Little

29.1 Approach to the poisoned patient

Lindsay Murray

Introduction

Drug overdose in adults usually occurs in the context of self-poisoning, which may be either recreational or an act of deliberate self-harm.

Deliberate self-poisoning accounts for 1–5% of all public hospital admissions in Australia [1,2]. The bulk of the medical management of cases presenting to hospital is carried out in the emergency department (ED) and the emergency physician is expected to be expert in the field. Although the management must vary considerably according to the nature and severity of the poisoning, some general principles apply.

Above all, it must be remembered that the acute overdose presentation is only a discrete time-limited event in the course of the underlying condition, which is usually psychiatric or social in origin.

Pathophysiology and clinical features

The effects of ingestion of pharmaceuticals or illicit drugs range from the non-toxic to the life threatening and may involve any system. Poisoning is a dynamic presentation and the patient may present at varying points in the time course of the poisoning. Consequently, rapid clinical deterioration or improvement may be observed after the initial presentation and assessment.

Acute morbidity and mortality from poisoning is usually a consequence of the cardiovascular, respiratory or central nervous system (CNS) complications of the poisoning. Less commonly, hepatic, renal or metabolic effects are potentially life threatening.

The most frequent life-threatening respiratory complication of poisoning is ventilatory failure, which is usually a consequence of CNS depression. Less commonly, it is secondary to ventilatory muscle paralysis. The frequency and depth of respirations are reduced. Respiratory failure may also be caused by direct pulmonary toxicity or complications, such as pulmonary aspiration or non-cardiogenic pulmonary oedema (Table 29.1.1).

Table 29.1.1

Toxic causes of respiratory failure

Central nervous system depression
Alcohols
Anticonvulsants
Antidepressants
Antihistamines
Barbiturates
Baclofen
Clonidine
Opioids
Phenothiazines
Sedative hypnotics
Weakness of ventilatory muscles
Botulism
Carbamate pesticides
Muscle relaxants
Organophosphorus pesticides and warfare agents
Snakebite
Strychnine
Pulmonary
ARDS
Cardiogenic pulmonary oedema
Non-cardiogenic pulmonary oedema
Pulmonary aspiration and pneumonitis

Paraquat

Image

ARDS: acute respiratory distress syndrome.

Cardiovascular manifestations of poisoning include tachycardia, bradycardia, hypertension, hypotension, conduction defects and arrhythmias (Table 29.1.2). Bradycardia is relatively rarely observed and is associated with a number of potentially life-threatening ingestions. Tachycardia is commonly observed and is usually benign. It may be due to intrinsic sympathomimetic or anticholinergic effects of a drug or a reflex response to hypotension or hypoxia. Hypotension is also commonly observed and may be due to a number of different causes (Table 29.1.2). Hypertension is unusual. Severe hypertension is usually associated with illicit drug use and is important because it may produce complications such as intracerebral haemorrhage.

Table 29.1.2

Cardiovascular effects of poisoning

Tachycardia
Anticholinergics

Quetiapine

Reflex response to hypotension
Sympathomimetics

Bradycardia (includes AV block)
β-Blockers
Calcium channel blockers
Clonidine
Digoxin
Hypotension
Fluid loss/third spacing
Myocardial depressants

Peripheral vasodilators
Hypertension
Anticholinergics
Sympathomimetics

Rhythm/ECG abnormalities
QRS prolongation (fast sodium channel blockade)

QT prolongation/torsades de pointes

Ventricular tachycardia/fibrillation

Ischaemia/infarction
Cocaine
Complication of hypoxia or hypotension

Image

CNS manifestations of poisoning include decreased level of consciousness, agitation or delirium, seizures and disordered temperature regulation. A decreased level of consciousness is a common presentation of poisoning and is associated with many drugs, some of which are listed in Table 29.1.1. Although usually a direct drug effect, CNS depression is occasionally secondary to hypoglycaemia, hypoxia or hypotension. Common causes of agitation or delirium following overdose are listed in Table 29.1.3. Toxic seizures are potentially life threatening and important causes are listed in Table 29.1.4.

Table 29.1.3

Toxic causes of agitation or delirium

Alcohol
Anticholinergic syndrome
Antidepressants

Atypical antipsychotic agents

Benzodiazepines and other sedative hypnotics
Cannabis
Hallucinogenic agents
Serotonin syndrome
Sympathomimetic syndrome

Theophylline
Withdrawal syndromes

Image

Table 29.1.4

Toxic causes of seizures

Amphetamines

Bupropion

Carbamazepine

Chloroquine

Cocaine

Isoniazid

Mefanamic acid

Theophylline

Tramadol

Tricyclic antidepressants

Venlafaxine

Hypothermia is usually a complication of environmental exposure secondary to a decreased level of consciousness or altered behaviour. Hyperthermia is a direct toxic effect and causes are listed in Table 29.1.5. Severe hyperthermia is rapidly lethal if not corrected.

Table 29.1.5

Toxic causes of hyperthermia

Amphetamines

Anticholinergics

Cocaine

MAO inhibitors

Salicylates

Serotonin syndrome

Metabolic and other manifestations of poisoning include hyper- and hypoglycaemia, hyper- and hyponatraemia, acidosis and alkalosis and hepatic failure.

Acute poisoning is distinguished from many other forms of acute illness in that, given appropriate supportive care over a relatively short period, a full recovery can usually be expected. A small number of potentially fatal poisonings may demonstrate progressive toxicity despite full supportive care. These are the so-called cellular toxins and include colchicine, iron, salicylate, cyanide, paracetamol, theophylline and digoxin. In some of these cases, early aggressive gastrointestinal decontamination, timely administration of antidotes or the institution of techniques of enhanced elimination may be life saving.

Mortality or morbidity may also result from specific complications of a poisoning. These include trauma, pulmonary aspiration, adult respiratory distress syndrome, rhabdomyolysis, renal failure and hypoxic encephalopathy. These complications usually occur prior to arrival in the ED.

Pulmonary aspiration frequently complicates a period of decreased level of consciousness or a seizure. It is a leading cause of in-hospital morbidity and mortality following overdose. This complication is characterized by rapid onset of dyspnoea, cough, fever, wheeze and cyanosis.

Rhabdomyolysis occurs as a direct toxic effect (rare) or secondary to excessive muscular hyperactivity, seizures, hyperthermia or prolonged coma with direct muscle compression. The urine is dark and acute renal failure can develop secondary to tubular deposition of myoglobin.

Assessment

Risk assessment

A risk assessment should be made as soon as possible in the management of the poisoned patient. Only resuscitation is a greater priority (Table 29.1.6). Risk assessment is a distinct quantitative cognitive step through which the clinician attempts to predict the likely clinical course and potential complications for the individual patient at that particular presentation [3]. An accurate risk assessment allows informed decision making in regard to all subsequent management steps including duration and intensity of supportive care and monitoring, screening and specialized testing, decontamination, enhanced elimination, antidotes and disposition. Factors that are taken into account when formulating this risk assessment include: the agent(s), the dose, the time since ingestion, the clinical features present and patient factors (Table 29.1.6). Specialized testing may refine risk assessment. Access to specialized poisons information in the form of a poisons information centre or in-house databases is often necessary to formulate an accurate risk assessment.

Table 29.1.6

Risk assessment-based approach to poisoning

Image

Reproduced from Murray L, Daly F, Little M, Cadogan M. Toxicology handbook, 2nd edn. Sydney: Elsevier; 2011.

History

Every effort should be made to obtain information as to the type and dose of drug ingested, the time of ingestion and the progression of symptoms since ingestion. History provided by the patient, if they are awake, is usually reliable and should not be dismissed.

Physical examination

The focused physical examination of the poisoned patient aims to:

The initial physical examination of the overdose patient in many ways parallels the primary survey of the trauma patient. The airway, breathing and circulation are assessed and stabilized as necessary. The level of consciousness should be assessed, the presence of seizure activity noted and the blood glucose and temperature measured.

A more complete examination is carried out when the patient is stable. This should include a full neurological examination, including assessment of the level of consciousness and mental status, pupil size, muscle tone and movements and the presence or absence of focal neurological signs. Poisoning normally causes global CNS depression and focal signs suggest an alternative diagnosis or a CNS complication, such as cerebral haemorrhage.

Other features that should be specifically sought are any evidence of associated trauma, the state of hydration, the condition of the skin, in particular the presence of pressure areas, the presence or absence of bowel sounds and the condition of the urine.

Several toxic autonomic syndromes, or ‘toxidromes’, have been described in relation to poisoning. The principal ones are listed in Table 29.1.7. Identification of these syndromes may narrow the differential diagnosis in cases of unknown poisoning.

Table 29.1.7

Toxic autonomic syndromes or ‘toxidromes’

Toxidrome Features Common causes
Anticholinergic Agitated delirium Antihistamines
Tachycardia Benztropine
Hyperthermia Carbamazepine
Dilated pupils Phenothiazines
Dry flushed skin Plant poisonings
Urinary retention Tricyclic antidepressants
Ileus  
Mixed cholinergic Brady- or tachycardia Organophosphates
Hypo- or hypertension Carbamates
Miosis or mydriasis  
Sweating  
Increased bronchial secretion  
Gastrointestinal hyperactivity  
Muscle weakness  
Fasciculations  
Mixed α- and β-adrenergic Hypertension Amphetamines
Tachycardia Cocaine
Mydriasis  
Agitation  
β-Adrenergic Hypotension Caffeine
Tachycardia Salbutamol
Hypokalaemia Theophylline
Hyperglycaemia  
Serotonin Altered mental status Amphetamines
Autonomic dysfunction Antihistamines
Fever Monoamine oxidase inhibitors
Hypertension NSSRIs
Sweating SSRIs
Tachycardia Tricyclic antidepressants
Motor dysfunction (Usually combined overdose)
Hyperreflexia  
Hypertonia (esp. lower limbs)  
Myoclonus  

Image

NSSRI: non-selective serotonin re-uptake inhibitor; SSRI: selective serotonin re-uptake inhibitor.

Poisons information

Information on the clinical course and toxic doses of specific pharmaceutical and non-pharmaceutical poisons is available on a 24 h basis throughout Australia by telephoning 131126. The poison information centres are staffed by trained poisons information specialists and are also able to refer cases to clinical toxicologists for consultation.

Treatment

The management of poisoning should be approached in a systematic way. Following initial resuscitation, further treatment is informed by the risk assessment (see Table 29.1.6).

Resuscitation, supportive care and monitoring

Supportive care is the key element in the management of poisoning. The vast majority of poisonings result in temporary dysfunction of one or more of the body systems. If appropriate support of the system in question is instituted in a timely fashion and continued until the toxic substance is metabolized or excreted, a good outcome can be anticipated. In severe poisonings, supportive care may be very aggressive and possible interventions are listed in Table 29.1.8.

Table 29.1.8

Supportive care measures for the poisoned patient

Airway Endotracheal intubation
Breathing Supplemental oxygen
Ventilation
Circulation Intravenous fluids
Inotropes
Antihypertensives
Antiarrhythmics
Defibrillation/cardioversion
Cardiac pacing
Cardiopulmonary bypass
Metabolic Hypertonic dextrose
Hypertonic saline
Insulin/dextrose
Calcium salts
Sodium bicarbonate
Agitation/delirium Benzodiazepines
Butyrophenones
Seizures Benzodiazepines
Barbiturates
Body External rewarming
Temperature External cooling
Impaired renal function Rehydration
Haemodialysis

Image

The specific supportive management of a number of manifestations or complications of poisoning warrants further mention insofar as it may differ from the standard management of such conditions with other aetiologies.

Cardiopulmonary arrest from poisoning should be aggressively resuscitated. Direct current cardioversion is rarely successful in terminating toxic arrhythmias and should not take precedence over establishing adequate ventilation and oxygenation, cardiac compressions, correction of acidosis or hypovolaemia and the administration of specific antidotes. Resuscitative efforts should be continued beyond the usual time frame. In cardiac arrest due to drugs with direct cardiac toxicity, the use of cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO) until the drug is metabolized may be life saving.

In general, intravenous benzodiazepines are the drugs of choice for control of toxic seizures. Large doses may be required. Hypoxia and hypoglycaemia must be corrected if they are contributory factors. Patients with toxic seizures do not generally need long-term anticonvulsant therapy. Isoniazid-induced seizures are difficult to control without administration of an adequate dose of the specific antidote, pyridoxine.

The management of pulmonary aspiration is essentially supportive, with supplemental oxygenation and intubation and mechanical ventilation if necessary. Neither prophylactic antibiotics nor corticosteroids have been shown to be helpful in the management of this condition, which is essentially a chemical pneumonitis.

Toxic hypertension rarely requires specific therapy. Most cases are mild and simple observation is sufficient. Agitation or delirium is a feature of many intoxications associated with hypertension and adequate sedation with benzodiazepines usually lowers the blood pressure. Severe toxic hypertension is most likely in toxicity from cocaine or amphetamine-type drugs and treatment may be indicated to avoid complications, such as cardiac failure or intracerebral haemorrhage. The drug of choice in this situation is sodium nitroprusside by intravenous infusion. The extremely short duration of action of this vasodilator allows accurate control of hypertension during the toxic phase and avoids the development of hypotension once toxicity begins to wear off.

Management of rhabdomyolysis consists of treatment of the causative factors, fluid resuscitation and careful monitoring of fluids and electrolytes. The role of mannitol and urinary alkalinization in reducing the risk of renal failure is not clear. Established acute renal failure requires haemodialysis, often for up to 6 weeks.

Decontamination

The aim of decontamination of the gastrointestinal tract is to bind or remove ingested material before it is absorbed into the circulation and able to exert its toxic effects. This is a very attractive concept and has long been considered one of the fundamental interventions in management of the overdose patient.

However, gastrointestinal decontamination should not be regarded as a routine procedure in the management of the patient presenting to the ED following an overdose. The decision to perform gastrointestinal decontamination and the choice of method should be based on an assessment of the likely benefit, the likely risk and the resources required. Gastrointestinal decontamination should only be considered where there is likely to be a significant amount of a significantly toxic material remaining in the gut. It is never indicated when the risk assessment predicts a benign course. Efforts at decontamination technique should never take precedence over the institution of appropriate supportive care.

Three basic approaches to gastrointestinal decontamination are available: gastric emptying, administration of an adsorbent and catharsis.

Gastric emptying can be attempted by the administration of an emetic, most commonly syrup of ipecac, or by gastric lavage. In volunteer studies, both of these techniques removed highly variable amounts of marker substances from the stomach even if performed immediately after ingestion and the effect diminished rapidly with time to the point of being negligible after 1 hour [4,5]. Clinical outcome trials have failed to demonstrate improved outcome as a result of routine gastric emptying in addition to administration of activated charcoal, except, perhaps, in patients presenting unconscious within 1 h of ingestion [68].

The principal adsorbent available to clinicians is activated charcoal (AC), which effectively binds most pharmaceuticals and chemicals, and is currently the decontamination method of choice for most poisonings. Materials that do not bind well to charcoal are listed in Table 29.1.9.

Charcoal is ‘activated’ by treatment in acid and steam at high temperature. This process removes impurities and greatly increases the surface area available for binding. Activated charcoal (AC) is packaged as a 50 g dose premixed with water or sorbitol, which is likely to be sufficient for the majority of ingestions. Adult patients are usually able to drink AC slurry from a cup. If the level of consciousness is too impaired to allow this, they should be intubated first. Administration of AC is absolutely contraindicated unless the patient has an intact or protected airway.

Volunteer studies demonstrate that the effect of AC diminishes rapidly with time and that the greatest benefit occurs if it is administered within 1 h. There is as yet no evidence that AC improves clinical outcome [9].

There is no evidence to suggest that the addition of a cathartic, such as sorbitol, to AC improves clinical outcome [10].

Apart from rarely employed endoscopic and surgical techniques, whole-bowel irrigation (WBI) is the most aggressive form of gastrointestinal decontamination. Polyethylene glycol solution (Golytely is administered via a nasogastric tube at a rate of 2 L/h until a clear rectal effluent is produced. This usually takes about 6 h and requires one-to-one nursing. In volunteer studies, this technique reduced the absorption of slow-release pharmaceuticals and so may be of benefit in life-threatening overdoses of these agents. Again, clinical benefit has not yet been conclusively demonstrated [11]. The use of WBI has also been reported in the management of potentially toxic ingestions of iron, lead and packets of illicit drugs. Whole-bowel irrigation is contraindicated if there is evidence of ileus or bowel obstruction and in patients who have an unprotected airway or haemodynamic compromise.

Enhanced elimination

A number of techniques are available to enhance the elimination of toxins from the body. Their use is rarely indicated, as only a very few drugs capable of causing severe poisoning have pharmacokinetic parameters that render them amenable to these techniques (Table 29.1.10).

Table 29.1.10

Techniques of enhanced elimination

Technique Suitable toxin
Multiple-dose activated charcoal Carbamazepine
Dapsone
Phenobarbitone
Phenytoin
Theophylline
Urinary alkalinization Phenobarbitone
Salicylate
Haemodialysis Ethylene glycol
Lithium
Metformin lactic acidosis
Methanol
Salicylate
Theophylline
Valproic acid
Charcoal haemoperfusion Theophylline

Image

Multiple-dose AC (25–50 g every 3–4 h) may enhance drug elimination by interrupting the enterohepatic circulation or by ‘gastrointestinal dialysis’. Gastrointestinal dialysis is the movement of a toxin across the gastrointestinal wall from the circulation into the gut down a concentration gradient that is maintained by charcoal binding. For this technique to be effective, a drug must undergo considerable enterohepatic circulation or, in the case of ‘gastrointestinal dialysis’, have a small volume of distribution, small molecular weight, low protein binding, slow endogenous elimination and bind to charcoal [12]. The advantages of this technique are that it is non-invasive and simple to carry out.

Alkalinization of the urine enhances urinary excretion of drugs that are filtered at the glomerulus and are unable to be reabsorbed across the tubular epithelium when in an ionized form at alkaline pH. For elimination to be effectively enhanced by this method, the drug must be predominantly eliminated by the kidneys in the unchanged form, have a low pKa, be distributed mainly to the extracellular fluid compartment and be minimally protein bound.

Haemodialysis (HD) and haemoperfusion (HP) are both very invasive techniques and for that reason are reserved for potentially life-threatening intoxications. Only a small number of drugs that have small volumes of distribution, slow endogenous clearance rates, small molecular weights (HD) and bind to charcoal (HP) will have their rates of elimination significantly enhanced by these procedures.

Antidotes

Very few drugs have effective antidotes. Occasionally, however, timely use of an antidote may be life saving or substantially reduce morbidity, time in hospital or resource requirements. Antidotes that may be indicated in the ED setting are listed in Table 29.1.11. However, it must be remembered that antidotes are also drugs and are frequently associated with adverse effects of their own. An antidote should only be used where a specific indication exists and then only at the correct dose, by the correct route and with appropriate monitoring. Because many antidotes are so infrequently used, obtaining sufficient supplies when the need arises can be difficult. Every ED must review its stocking of antidotes and have a plan for obtaining further supplies should the need arise.

Table 29.1.11

Useful emergency antidotes

Poisoning Antidote
Atropine Physostigmine
Benzodiazepines Flumazenil
Cyanide Dicobalt edetate, hydroxocobalamin
Digoxin Digoxin-specific
Fab fragments
Insulin Dextrose
Iron Desferoxamine
Isoniazid Pyridoxine
Methaemoglobinaemia Methylene blue
Methanol and ethylene glycol Ethanol, fomepizole
Organophosphates and carbamates Atropine, oximes
Opioids Naloxone
Paracetamol N-acetyl cysteine
Sulphonylureas Dextrose, octreotide
Tricyclic antidepressants Sodium bicarbonate
Warfarin, brodifacoum Vitamin K

Differential diagnosis

It is essential to exclude important non-toxic diagnoses in the patient presenting with coma or altered mental status presumed to be due to drug overdose. These diagnoses include head injury, intracerebral haemorrhage or infarction, CNS infection, hyponatraemia, hypoglycaemia, hypo- or hyperthermia, post-ictal states and psychiatric disorders.

Clinical investigations

Investigations should only be performed if they are likely to affect the management of the patient. They are employed as either screening tests or for specific purposes.

In poisoning, screening tests aim to identify occult toxic ingestions for which early specific treatment might improve outcome. The recommended screening tests for acute poisoning are the 12-lead ECG and the serum paracetamol level. The ECG is used to exclude conduction defects which may predict potentially life-threatening cardiotoxicity. The serum paracetamol is useful to ensure that paracetamol poisoning is diagnosed within the time available for effective antidotal treatment.

Other specific investigations may be indicated to exclude important differential diagnoses, confirm a specific poisoning for which significant complications might be anticipated, assess the severity of intoxication, assess response to treatment or assess the need for a specific antidote or enhanced elimination technique.

The patient with only minor manifestations of poisoning may require no other blood tests apart from a screening paracetamol level. Pregnancy should be excluded in women of childbearing age by serum or urine β-HCG if necessary. More seriously ill patients may require electrolyte, renal and liver function tests and a full blood count, creatine kinase and arterial blood gases. Urinalysis reveals myoglobinuria in significant rhabdomyolysis.

Routine qualitative drug screening of urine or blood in the overdose patient is rarely useful in planning management.

Measurement of serum drug concentrations is only useful if this provides important diagnostic or prognostic information or assists in planning management. Some drug levels that may be useful are listed in Table 29.1.12. For most cases, drug overdose management is guided by clinical findings and not by drug levels. Some drugs commonly taken in overdose for which serum concentrations are of no value in planning management are listed in Table 29.1.13.

Table 29.1.12

Drug levels that may be helpful in the management of selected cases of overdose

Carbamazepine

Digoxin

Dilantin

Lithium

Iron

Paracetamol

Phenobarbitone

Salicylate

Theophylline

Valproate

Table 29.1.13

Drug levels that are not helpful in the management of overdose

CNS drugs Cardiovascular drugs
Antidepressants ACE inhibitors
Benzodiazepines β-Blockers
Benztropine Calcium channel blockers
Cocaine Clonidine
Newer antipsychotics  
Opiates  
Phenothiazines  

Radiology has a limited role in the management of overdose. A chest X-ray is indicated in any patient with a significantly decreased level of consciousness, seizures or hypoxia. It may show evidence of pulmonary aspiration. A computed tomography scan of the head may be indicated to exclude other intracranial pathology in the patient with an altered mental status. The abdominal X-ray is useful in evaluating overdose of radiopaque metals including iron, lithium, potassium, lead and arsenic.

Disposition

Both the medical and the psychiatric disposition of the overdose patient must be considered. A good risk assessment is essential to determining timely and safe disposition.

The majority of overdose patients who remain stable at 4–6 h after the ingestion do not need further close monitoring and may be admitted to a non-monitored bed until manifestations of toxicity completely resolve. An emergency observation ward is ideal for this purpose.

Any patient who develops clinical manifestations of intoxication severe enough to require the institution of specific supportive care measures requires admission to an intensive care environment. A few patients will require admission for prolonged monitoring based on the history of the ingestion. For example, anyone with a history of ingestion of colchicine, organophosphates, slow-release theophylline or slow-release calcium channel blockers requires admission because of the possibility of delayed onset of severe toxicity.

Psychiatric evaluation of deliberate self- poisoning cases is indicated as soon as the patient’s medical condition permits. All such patients must be continuously supervised until the psychiatric evaluation has taken place.

References

1. McGrath J. A survey of deliberate self-poisoning. Med J Aust. 1989;150:317–322.

2. Pond SM. Prescription for poisoning. Med J Aust. 1995;162:174–175.

3. Murray L, Daly F, Little M, Cadogan M, eds. Toxicology handbook. 2nd ed. Sydney: Elsevier Australia; 2011.

4. American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: ipecac syrup. J Toxicol Clin Toxicol. 2004;42:133–143.

5. American Academy of Clinical Toxicology, European Assoication of Poison Centres and Clinical Toxicologists. Position paper: gastric lavage. J Toxicol Clin Toxicol. 2004;42:933–943.

6. Kulig K, Bar-Or D, Kantrill SV, et al. Management of acutely poisoned patients without gastric emptying. Ann Emerg Med. 1990;14:562–567.

7. Merigian KS, Woodard M, Hedges JR, et al. Prospective evaluation of gastric emptying in the self-poisoned patient. Am J Emerg Med. 1990;8:479–483.

8. Pond SM, Lewis-Driver DJ, Williams G, et al. Gastric emptying in acute overdose: a prospective randomised controlled trial. Med J Aust. 1995;163:345–349.

9. American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: single-dose activated charcoal. J Toxicol Clin Toxicol. 2005;43:61–87.

10. American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: cathartics. J Toxicol Clinl Toxicol. 2004;42:243–253.

11. American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: whole bowel irrigation. J Toxicol Clin Toxicol. 2004;24:843–854.

12. Chyka PA. Multiple-dose activated charcoal and enhancement of systemic drug clearance: summary of studies in animals and human volunteers. Clin Toxicol. 1995;33:399–405.

29.2 Cardiovascular drugs

Betty Shuk Han Chan and Angela Chiew

Calcium channel blockers and β-blockers

Introduction

The calcium channel blockers (CCBs) and β-blockers are widely prescribed in the community. In overdose, they present with similar clinical pictures of potentially life-threatening impairment of cardiac function. The management of both types of overdose is similar and they are discussed together.

Pharmacokinetics

Standard CCB preparations are rapidly absorbed from the gastrointestinal tract, with onset of action occurring within 30 min. Pharmacokinetic parameters are shown in Table 29.2.1

Buy Membership for Emergency Medicine Category to continue reading. Learn more here